GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (NAS:SRPT) » Definitions » 5-Year ROIIC %

SRPT (Sarepta Therapeutics) 5-Year ROIIC % : 7.16% (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Sarepta Therapeutics 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Sarepta Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was 7.16%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Sarepta Therapeutics's 5-Year ROIIC % or its related term are showing as below:

SRPT's 5-Year ROIIC % is ranked better than
66.67% of 1302 companies
in the Biotechnology industry
Industry Median: -22.27 vs SRPT: 7.16

Sarepta Therapeutics 5-Year ROIIC % Historical Data

The historical data trend for Sarepta Therapeutics's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics 5-Year ROIIC % Chart

Sarepta Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -82.53 -45.13 -25.75 -62.41 7.16

Sarepta Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 7.16 - - -

Competitive Comparison of Sarepta Therapeutics's 5-Year ROIIC %

For the Biotechnology subindustry, Sarepta Therapeutics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics's 5-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's 5-Year ROIIC % falls into.



Sarepta Therapeutics 5-Year ROIIC % Calculation

Sarepta Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -275.992632 (Dec. 2023) - -342.9751068 (Dec. 2018) )/( 1287.218 (Dec. 2023) - 351.077 (Dec. 2018) )
=66.9824748/936.141
=7.16%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Sarepta Therapeutics  (NAS:SRPT) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Sarepta Therapeutics 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sarepta Therapeutics Business Description

Traded in Other Exchanges
Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Executives
Ian Michael Estepan officer: Chief Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Michael Andrew Chambers director 215 FIRST STREET, CAMBRIDGE MA 02142
Bilal Arif officer: Chief Tech Ops Officer 215 FIRST STREET, CAMBRIDGE MA 02129
Ryan Edward Brown officer: SVP, General Counsel 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Kathryn Jean Boor director 3736 S. MAIN STREET, MARION NY 14505
Wigzell Hans Lennart Rudolf director OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935
Stephen Mayo director 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Richard Barry director 285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Douglas S Ingram director, officer: President & CEO 2525 DUPONT DR, IRVINE CA 92612
Louise Rodino-klapac officer: Chief Scientific Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
M Kathleen Behrens director 6701 KAISER DRIVE, FREMONT CA 94555
Joseph Bratica officer: Principal Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
David T Howton officer: SVP, General Counsel VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
John C Martin director 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Sandesh Mahatme officer: Senior Vice President, CFO C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901